Estradiol Undecylate

Estradiol Undecylate

SCHEMBL453172

CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C

nearest known ligand 0.93

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 8/20 0.93
MAPT P10636 7/20 0.93
KMT2A Q03164 7/20 0.93
CYP3A4 P08684 6/20 0.93
MEN1 O00255 6/20 0.93
ESR1 P03372 6/20 0.93
TP53 P04637 3/20 0.93
ALOX15 P16050 3/20 0.93
SMN1; SMN2 Q16637 3/20 0.93
PGR P06401 3/20 0.93
AR P10275 3/20 0.93
ADORA3 P0DMS8 2/20 0.93
PTGS1 P23219 2/20 0.93
PDE3A Q14432 2/20 0.93
POLB P06746 1/20 0.93
CHRM1 P11229 1/20 0.93
TBXA2R P21731 1/20 0.93
ATM Q13315 1/20 0.93
USP2 O75604 1/20 0.93
MAPK1 P28482 3/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9418881 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
SCHEMBL7751687 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
Estradiol Enanthate SCHEMBL28129756 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
SCHEMBL1315378 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
Estradiol Enanthate SCHEMBL547096 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
SCHEMBL3500119 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
Estradiol Undecylate SCHEMBL23728444 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
SCHEMBL11596845 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
SCHEMBL17419452 1.00 LMNA (0.93) LMNAMAPTKMT2ACYP3A4MEN1
Estradiol Valerate SCHEMBL6195972 0.96 LMNA (1.00) LMNAMAPTKMT2ACYP3A4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 534 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12310928-B2 Enthesis healing UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2025-05-27 US claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 US claimed
EP-3863708-B1 MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING BATTELLE MEMORIAL INSTITUTE (US) 2024-09-11 EP claimed
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2023-03-23 US claimed
WO-2022182523-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 WO claimed
WO-2021158573-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
WO-2021158575-A1 COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES Natural Extraction Systems, LLC (US) 2021-08-12 WO claimed
US-20180305742-A1 USE OF ESTROGENIC COMPOUNDS TO MANIPULATE THE BACTERIAL COMPOSITION OF VAGINAL COMMUNITIES UNIVERSITY OF IDAHO (US) 2018-10-25 US claimed
US-8110565-B2 Of the ACE inhibitor ramipril; controlling the melting point by mixing with the free acid with the ramipril ethyl or methyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release NOVEN PHARMACEUTICALS, INC. (US) 2012-02-07 US claimed
EP-0346014-B1 Therapeutic product for the treatment of peri- or postmenopausal conditions ZENECA LTD (GB) 1994-08-03 EP claimed
US-5183814-A Administering estrogen and antiestrogen IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-02-02 US claimed
EP-0256668-B1 METHOD FOR TREATING MALE SEXUAL DYSFUNCTION UNIVERSITY OF FLORIDA (US) 1992-11-04 EP claimed
EP-0346014-A1 Therapeutic product for the treatment of peri- or postmenopausal conditions ZENECA LIMITED (GB) 1989-12-13 EP claimed
US-4863911-A Method for treating male sexual dysfunction UNIVERSITY OF FLORIDA (US) 1989-09-05 US claimed
EP-0256668-A2 Method for treating male sexual dysfunction UNIVERSITY OF FLORIDA (US) 1988-02-24 EP claimed
EP-0220844-A2 Use of estrogen-dihydropyridine compounds for weight control UNIVERSITY OF FLORIDA (US) 1987-05-06 EP claimed
US-4617298-A STEROIDS UNIVERSITY OF FLORIDA (US) 1986-10-14 US claimed
US-4298594-A BENEFICIAL ALTERATION OF PHARMACODYNAMICS ARTHUR D. LITTLE, INC. (US) 1981-11-03 US claimed
US-4071623-A ESTROGENICALLY ACTIVE STEROIDS AKZONA INCORPORATED (US) 1978-01-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230089351-A1 METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES FABP2, FABP4, GUSB LMNA 344/4885MAPT 3926/4885KMT2A 4742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.